BICYCLE THERAPEUTICS PLC

• ⚠

  Confirmation statement overdue

  Due 2026-08-16.

Figures converted to GBP from USD at 0.743 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

1. BICYCLE THERAPEUTICS PLC 2019-05-22 → present
2. BICYCLE THERAPEUTICS LIMITED 2017-10-27 → 2019-05-22

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“At 31 December 2025, the Company had cash and cash equivalents of $628.1 million and the directors estimate the Company's existing cash and cash equivalents at the date of approval of these financial statements is sufficient to fund the Company's operating expenses for the foreseeable future for at least 12 months from the date of that approval and that is therefore appropriate to prepare these financial statements on a going concern basis.”

Group structure

1. BICYCLE THERAPEUTICS PLC · parent
   1. BicycleTx Limited 100% · United Kingdom · Research and development of novel bicyclic peptides
   2. BicycleRD Limited 100% · United Kingdom · Research and development of novel bicyclic peptides
   3. Bicycle Therapeutics Inc. 100% · United States · Research and development of novel bicyclic peptides

Significant events

• “In March 2026, the Company announced the strategic reprioritisation of its clinical portfolio to focus on its promising pipeline of next-generation therapeutics, including nuzefatide pevedotin as well as next-generation Bicycle conjugates, including BRC molecules.”
• “In April 2026, the Parent Company completed an assessment, inclusive of external legal advice, of the treatment of deemed distributions for tax losses historically surrendered to it by BicycleTx Limited and BicycleRD Limited.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

20

last 12 months

Capital events

14

last 24 months

Officers appointed

3

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.